CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- InVivo Therapeutics Holdings Corp. (NVIV) today announced that InVivo CEO Mark Perrin has been featured on The Wall Street Transcript (TWST), a service for investors and industry researchers that provides fresh commentary and insight through interviews with CEOs. The candid conversation about the company and InVivo’s Neuro-Spinal Scaffold was released on August 4 and is part of TWST’s company interview series. The full interview is available on InVivo’s website at http://www.invivotherapeutics.com/investor-relations/news/in-the-news/.
“We were honored to have InVivo selected as one of The Wall Street Transcript’s featured companies,” Mr. Perrin said, “Personally, I was happy to have the chance to talk about developments at InVivo, not the least of which is the technology itself. We’ve achieved some important milestones this year, including getting a top-notch leadership team in place and the initiation of our clinical program. I talk about those milestones – and others – in the interview, as well as our plans going forward.”
He added, “This kind of exposure is important to our goal of disseminating information to investors and to potential patients. Everything we’re doing at InVivo, ultimately, is for the patient, and to improve their quality of life after the devastation of a spinal cord injury. We appreciate The Wall Street Transcript helping us get the word out about this exciting technology.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "believe," "anticipate," "intend," "estimate," "will," "may," "should," "expect" and similar expressions. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to successfully open additional clinical sites for enrollment; the timing of the Institutional Review Board process; the Company’s ability to obtain FDA approval to commercialize its products; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as amended, and its other filings with the SEC, including the Company’s Form 10-Qs and current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.